OUTCOME AND FOLLOW UP
Tolerance of treatment was excellent, without any side effect. The
patient has not experienced any rash flare since the start of treatment
and pruritus has regressed. The dry cough and dyspnea have also
disappeared, and the obstructive ventilatory disorder has improved on
the respiratory function test. Biologically, the eosinophil count
returned to normal (130/mm3), confirming the obtention of a complete
hematologic remission (CHR), white blood cells were at 6590/mm3. The
other blood cell lines were all normal. The eosinophil count remained
definitely and continuously normal. In February 2022, because of the
stability of the eosinophil count under Imatinib for 6 years, a check of
the FIP1L1-PDGFRA transcript was performed and was found negative,
confirming the obtention of a CMR. Therefore, Imatinib was discountinued
provided that regular monitoring of the count blood cell and the
FIP1L1-PDGFRA transcript were done every 3 months. Imatinib was stopped
in February 2022. Three months later, the FIP1L1-PDGFRA transcript was
still undetectable. In addition, the patient has no clinical symptoms:
no cough, no rash, no pruritus, no tumor syndrome. The count blood cell
shows a normal eosinophil count of 490/mm3. He did not show any signs of
TKI withdrawal syndrome either. Nine months after Imatinib withdrawal,
CMR is sustained.